LICENSE AGREEMENTS	6 Months Ended
Jun. 30, 2025
LICENSE AGREEMENTS
LICENSE AGREEMENTS	NOTE 15 – LICENSE AGREEMENTS As of June 30, 2025, the Company had nine commercial license and supply agreements outstanding, whereby the Company will receive a royalty or other proceeds from the specified product revenues from the licensor, if and when the underlying products are approved and commercialized or sold via compassionate use or early access programs. No royalty revenues have been received through June 30, 2025 from any of these agreements.

LICENSE AGREEMENTS

6 Months Ended

Jun. 30, 2025

NOTE 15 – LICENSE AGREEMENTS

As of June 30, 2025, the Company had nine commercial license and supply agreements outstanding, whereby the Company will receive a royalty or other proceeds from the specified product revenues from the licensor, if and when the underlying products are approved and commercialized or sold via compassionate use or early access programs. No royalty revenues have been received through June 30, 2025 from any of these agreements.

Quoin Pharmaceuticals, Ltd. 10-Q